The effect of oral folic acid on glutathione, glycaemia and lipids in type 2 diabetes

Diabetes, Nutrition and Metabolism - Clinical and Experimental

Volumn 17, Issue 2, 2004, Pages 95-102

  Child, D F ^a   Hudson, P R ^a   Jones, H ^a   Davies, G K ^a   De, P ^a   Mukherjee, S ^a   Brain, A M ^b   Williams, C P ^a   Harvey, J N ^a  

^a WREXHAM MAELOR HOSPITAL   (United Kingdom)

^b ROYAL GWENT HOSPITAL   (United Kingdom)

Author keywords

Folic acid; Glutathione; Homocysteine; Microalbuminuria; Type 2 diabetes

Indexed keywords

CHOLESTEROL; FOLIC ACID; GLUTATHIONE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; METFORMIN; PYRIDOXINE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD VESSEL FUNCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID METABOLISM; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ALBUMINURIA; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; ERYTHROCYTES; FEMALE; FOLIC ACID; GLUTATHIONE; HEMOGLOBIN A, GLYCOSYLATED; HOMOCYSTEINE; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; METFORMIN; MIDDLE AGED; TRIGLYCERIDES; VITAMIN B 6;

EID: 2942620482     PISSN: 03943402     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Wall R.T., Harlan J.M., Harker L.A., Striker G.E.: Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb. Res. (Suppl.) 18: 113-121, 1980.
2. Fiorina P., Lanfredini M., Montanari A., Peca M.G., Veronelli A., Mello A., Astorri E., Craveri A.: Plasma homocysteine and folate are related to arterial blood pressure in type 2 diabetes mellitus. Am. J. Hypertens. 11: 1100-1107, 1998.
3. Stehouwer C.D., Gall M.A., Hougaard P., Jakobs C., Parving H.H.: Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria. Kidney Int. 55: 308-314, 1999.
4. Graham I.M., Daly L.E., Refsum H.M., Robinson K., Brattstrom L.E., Ueland P.M., Palma-Reis R.J., Boers G.H., Sheahan R.G., Israelsson B., Viterwaal C.S., Meleady R., McMaster D., Verhoef P., Witteman J., Rubba P., Bellet H., Wautrecht J.C., de Walk H.W., Sales Luis A.C., Parrot-Rouland F.M., Tan K.S., Higgins I., Garcon D., Andria G. et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. J.A.M.A. 277: 1775-1778, 1997.
5. Stehouwer C.D., Gall M.A., Twisk J.W., Knudsen E., Emeis J.J., Parving H.H.: Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51: 1157-1165, 2002.
6. Lanfredini M., Fiorina P., Peca M.G., Veronelli A., Mello A., Astorri E., Dall'Aglio P., Craveri A.: Fasting and post-methionine load homocyst(e)ine values are correlated with microalbuminuria and could contribute to worsening vascular damage in non-insulin-dependent diabetes mellitus patients. Metabolism 47: 915-921, 1998.
7. Hofmann M.A., Kohl B., Zumbach M.S., Borcea V., Bierhaus A., Henkels M., Amiral J., Fiehn W., Ziegler R., Wahl P., Nawroth P.P.: Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 20: 1880-1886, 1997.
8. Valle D., Pai G.G., Thomas G.H., Pyeritz R.E.: Homocystinuria due to a cystathionine beta-synthase deficiency: clinical manifestations and therapy. Johns Hopkins Med. J. 146: 110-117, 1980.
9. Brattstrom L.: Vitamins as homocysteine-lowering agents. J. Nutr. 126: 1276S-1280S, 1996.
10. Boushey C.J., Beresford S.A., Omenn G.S., Motulsky A.G.: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J.A.M.A. 274: 1049-1057, 1995.
11. Homocysteine Lowering Trialists' Collaboration Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials B.M.J. 316: 894-898, 1998.
12. Thambyrajah J., Landray M.J., McGlynn F.J., Jones H.J., Wheeler D.C., Townend J.N.: Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure? Circulation 102: 871-875, 2000.
13. Woo K.S., Chook P., Lolin Y.I., Sanderson J.E., Metreweli C., Celermajer D.S.. Folic acid improves arterial endothelial function in adults with hyperhomocysteinemia. J. Am. Coll. Cardiol. 34: 2002-2006, 1999.
14. Harvey J.N., Hood K., Platts J.K., Devarajoo S., Meadows P.A.: Prediction of albumin excretion rate from albumin-to-creatinine ratio. Diabetes Care 22: 1597-1598, 1999.
15. Ranganath L.R., Baines M., Roberts N.B.: Homocysteine and thiol metabolites in vitamin B12 deficiency. Clin. Sci. (Lond.) 100: 111-116, 2001.
16. Levy J.C., Matthews D.R., Hermans M.P.: Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21: 2191-2192, 1998.
17. MacLeod J.M., Lutale J., Marshall S.M.: Albumin excretion and vascular deaths in NIDDM. Diabetologia 38: 610-616, 1995.
18. Niskanen L.K., Penttila I., Parviainen M., Uusitupa M.I.: Evolution, risk factors, and prognostic implications of albuminuria in NIDDM. Diabetes Care 19: 486-493, 1996.
19. Mezzano D., Pais E.O., Aranda E., Panes O., Downey P., Ortiz M., Tagle R., Gonzalez F., Quiroga T., Caceres M.S., Leighton F., Pereira J.: Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int. 60: 1844-1850, 2001.
20. Doshi S.N., McDowell I.F., Moat S.J., Lang D., Newcombe R.G., Kredan M.B., Lewis M.J., Goodfellow J.: Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide? Arterioscler. Thromb. Vasc. Biol. 21: 1196-1202, 2001.
21. Samiec P.S., Drews-Botsch C., Flagg E.W., Kurtz J.C., Sternberg P. Jr., Reed R.L., Jones D.P.: Glutathione in human plasma: decline in association with aging, age-related macular degeneration, and diabetes. Free Radic. Biol. Med. 24: 699-704, 1998.
22. Janosik M., Kery V., Gaustadnes M., Maclean K.N., Kraus J.P.: Regulation of human cystathionine beta-synthase by S-adenosyl-L-methionine: evidence for two catalytically active conformations involving an autoinhibitory domain in the C-terminal region. Biochemistry 40: 10625-10633, 2001.
23. Chaney S.G.: Principles of nutrition II, micronutrients. In: Devlin T.M. (Ed), Textbook of biochemistry with clinical correlations. J. Wiley and Sons, New York, 1982, pp. 1216-1218.
24. Lu S.C.: Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB J. 13: 1169-1183, 1999.
25. Jain S.K., Lim G.: Pyridoxine and pyridoxamine inhibits superoxide radicals and prevents lipid peroxidation, protein glycosylation, and (Na+ + K+)-ATPase activity reduction in high glucose-treated human erythrocytes. Free Radic. Biol. Med. 30: 232-237, 2001.
26. Lal K.J., Dakshinamurti K., Thliveris J.: The effect of vitamin B6 on the systolic blood pressure of rats in various animal models of hypertension. J. Hypertens. 14: 355-363, 1996.
27. Harripersad R., Burger F.J.: The effect of a subnormal dose of vitamin B6 on plasma lipid in the rat. Int. J. Vitam. Nutr. Res. 67: 95-101, 1997.
28. Verma S., Yao L., Dumont A.S., McNeill J.H.: Metformin treatment corrects vascular insulin resistance in hypertension. J. Hypertens. 18: 1445-1450, 2000.